BIO vs. JNJ: Bio-Rad Laboratories vs. Johnson & Johnson Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while JNJ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and Johnson & Johnson (JNJ) at 20.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

Johnson & Johnson (JNJ) at 25.74% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Johnson & Johnson (JNJ) reports EPS growth of 90.50%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

Both Bio-Rad Laboratories (BIO) at 0.18 and Johnson & Johnson (JNJ) at 0.55 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Johnson & Johnson (JNJ) at 41.92 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Johnson & Johnson (JNJ) at 8.16 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics